Low Absolute Lymphocyte Counts in the Peripheral Blood Predict Inferior Survival and Improve the International Prognostic Index in Testicular Diffuse Large B-Cell Lymphoma.

CNS prophylaxis absolute lymphocyte count diffuse large B-cell lymphoma extranodal lymphoma lymphopenia testicular lymphoma

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
20 Jul 2020
Historique:
received: 17 06 2020
revised: 14 07 2020
accepted: 15 07 2020
entrez: 24 7 2020
pubmed: 24 7 2020
medline: 24 7 2020
Statut: epublish

Résumé

Low absolute lymphocyte counts (ALC) and high absolute monocyte counts (AMC) are associated with poor survival in patients with diffuse large B-cell lymphoma (DLBCL). We studied the prognostic impact of the ALC and AMC in patients with testicular DLBCL (T-DLBCL). T-DLBCL patients were searched using Southern Finland University Hospital databases and the Danish lymphoma registry. The progression free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier and Cox proportional hazards methods. We identified 178 T-DLBCL patients, of whom 78 (44%) had a low ALC at diagnosis. The ALC did not correlate with survival in the whole cohort. However, among the patients treated with rituximab (R) containing regimen, a pre-therapeutic low ALC was associated with an increased risk of progression (HR 1.976, 95% CI 1.267-3.086,

Identifiants

pubmed: 32698344
pii: cancers12071967
doi: 10.3390/cancers12071967
pmc: PMC7409117
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Academy of Finland
ID : .
Organisme : Finnish Cancer Organizations
ID : .
Organisme : Sigrid Juselius Foundation
ID : .
Organisme : Karen Elise Jensens Fond
ID : .
Organisme : Helsingin Yliopisto
ID : .
Organisme : Helsingin ja Uudenmaan Sairaanhoitopiiri
ID : .
Organisme : Finnish Oncology Association
ID : .

Références

J Clin Oncol. 2003 Jan 15;21(2):266-72
pubmed: 12525518
Haematologica. 2014 Jan;99(1):125-30
pubmed: 23935023
Crit Rev Oncol Hematol. 2008 Feb;65(2):183-9
pubmed: 17962036
Ann Oncol. 2007 Jul;18(7):1209-15
pubmed: 17496307
Leukemia. 2010 Jul;24(7):1343-9
pubmed: 20485372
Am J Hematol. 2013 Apr;88(4):273-6
pubmed: 23460351
Clin Oncol (R Coll Radiol). 2012 Jun;24(5):358-65
pubmed: 22424983
Haematologica. 2020 Feb 20;:
pubmed: 32079690
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Blood. 2014 Jan 23;123(4):486-93
pubmed: 24282217
Leukemia. 2007 Oct;21(10):2227-30
pubmed: 17554383
Leuk Lymphoma. 2015;56(9):2563-8
pubmed: 25686648
J Clin Oncol. 2009 Nov 1;27(31):5227-32
pubmed: 19770371
Cancer. 2010 Sep 15;116(18):4283-90
pubmed: 20564149
Blood. 2004 Nov 1;104(9):2635-42
pubmed: 15226177
J Clin Oncol. 2003 Jan 1;21(1):20-7
pubmed: 12506165
Haematologica. 2019 Feb;104(2):338-346
pubmed: 30237271
Blood. 2017 Jun 8;129(23):3071-3073
pubmed: 28356247
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):501-8
pubmed: 15145169
Blood Rev. 2018 May;32(3):249-255
pubmed: 29289361
Blood Rev. 2018 Sep;32(5):400-415
pubmed: 29605154
Eur J Haematol. 2008 Dec;81(6):448-53
pubmed: 18691256
Eur J Cancer. 2019 Jul;115:27-36
pubmed: 31082690
Haematologica. 2015 Feb;100(2):238-45
pubmed: 25381134
Haematologica. 2018 Nov;103(11):1908-1914
pubmed: 30026337
Leukemia. 2011 Sep;25(9):1502-9
pubmed: 21606957
Leuk Lymphoma. 2012 Nov;53(11):2159-65
pubmed: 22551474
PLoS One. 2012;7(7):e41658
pubmed: 22911837
Leukemia. 2016 Feb;30(2):361-72
pubmed: 26308769
Semin Hematol. 2010 Apr;47(2):115-23
pubmed: 20350658
J Clin Oncol. 2006 Dec 20;24(36):5711-5
pubmed: 17116938
Br J Cancer. 2014 Sep 9;111(6):1072-9
pubmed: 25072255
Blood. 2016 Feb 18;127(7):869-81
pubmed: 26702065
Ann Oncol. 2017 Oct 1;28(10):2511-2516
pubmed: 28961838
J Immunother Cancer. 2019 Mar 28;7(1):85
pubmed: 30922400
Ann Oncol. 2018 Dec 1;29(12):2363-2370
pubmed: 30307529
Ann Oncol. 2014 Nov;25(11):2124-2133
pubmed: 24625454
Ann Hematol. 2012 Mar;91(3):375-82
pubmed: 21811783
Cancer Immunol Res. 2019 Apr;7(4):644-657
pubmed: 30745366
Oncotarget. 2018 May 4;9(34):23620-23627
pubmed: 29805761

Auteurs

Pauli Vähämurto (P)

Department of Oncology, Helsinki University Hospital, Comprehensive Cancer Center, 00290 Helsinki, Finland.
Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.

Marjukka Pollari (M)

Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.
Department of Oncology, Tampere University Hospital, 33520 Tampere, Finland.

Michael R Clausen (MR)

Department of Hematology, Vejle Hospital, 7100 Vejle, Denmark.

Francesco d'Amore (F)

Department of Hematology, Aarhus University Hospital, 8200 Aarhus, Denmark.

Sirpa Leppä (S)

Department of Oncology, Helsinki University Hospital, Comprehensive Cancer Center, 00290 Helsinki, Finland.
Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.

Susanna Mannisto (S)

Department of Oncology, Helsinki University Hospital, Comprehensive Cancer Center, 00290 Helsinki, Finland.
Applied Tumor Genomics Research Program, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland.

Classifications MeSH